518 related articles for article (PubMed ID: 31873723)
21. The hallmarks of cancer are also the hallmarks of wound healing.
MacCarthy-Morrogh L; Martin P
Sci Signal; 2020 Sep; 13(648):. PubMed ID: 32900881
[TBL] [Abstract][Full Text] [Related]
22. Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma.
Videla-Richardson GA; Morris-Hanon O; Torres NI; Esquivel MI; Vera MB; Ripari LB; Croci DO; Sevlever GE; Rabinovich GA
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008740
[TBL] [Abstract][Full Text] [Related]
23. Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer.
Losson H; Schnekenburger M; Dicato M; Diederich M
Molecules; 2016 Nov; 21(11):. PubMed ID: 27886118
[TBL] [Abstract][Full Text] [Related]
24. Galectin-1 and -9 in angiogenesis: a sweet couple.
Thijssen VL; Griffioen AW
Glycobiology; 2014 Oct; 24(10):915-20. PubMed ID: 24861051
[TBL] [Abstract][Full Text] [Related]
25. Galectins and microenvironmental niches during hematopoiesis.
Rabinovich GA; Vidal M
Curr Opin Hematol; 2011 Nov; 18(6):443-51. PubMed ID: 21912250
[TBL] [Abstract][Full Text] [Related]
26. Shaping the Immune Landscape in Cancer by Galectin-Driven Regulatory Pathways.
Rabinovich GA; Conejo-García JR
J Mol Biol; 2016 Aug; 428(16):3266-3281. PubMed ID: 27038510
[TBL] [Abstract][Full Text] [Related]
27. Untangling Galectin-Driven Regulatory Circuits in Autoimmune Inflammation.
Toscano MA; Martínez Allo VC; Cutine AM; Rabinovich GA; Mariño KV
Trends Mol Med; 2018 Apr; 24(4):348-363. PubMed ID: 29555188
[TBL] [Abstract][Full Text] [Related]
28. Untangling Galectin-Mediated Circuits that Control Hypoxia-Driven Angiogenesis.
Bannoud N; García PA; Gambarte-Tudela J; Sundblad V; Cagnoni AJ; Bach CA; Pérez Saez JM; Blidner AG; Maller SM; Mariño KV; Salatino M; Cerliani JP; Rabinovich GA; Croci DO
Methods Mol Biol; 2022; 2442():635-653. PubMed ID: 35320550
[TBL] [Abstract][Full Text] [Related]
29. YB-1: oncoprotein, prognostic marker and therapeutic target?
Lasham A; Print CG; Woolley AG; Dunn SE; Braithwaite AW
Biochem J; 2013 Jan; 449(1):11-23. PubMed ID: 23216250
[TBL] [Abstract][Full Text] [Related]
30. Galectins and Carcinogenesis: Their Role in Head and Neck Carcinomas and Thyroid Carcinomas.
Kindt N; Journe F; Ghanem GE; Saussez S
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258258
[TBL] [Abstract][Full Text] [Related]
31. Telomerase and hallmarks of cancer: An intricate interplay governing cancer cell evolution.
Kumar N; Sethi G
Cancer Lett; 2023 Dec; 578():216459. PubMed ID: 37863351
[TBL] [Abstract][Full Text] [Related]
32. Mevalonate metabolism in cancer.
Gruenbacher G; Thurnher M
Cancer Lett; 2015 Jan; 356(2 Pt A):192-6. PubMed ID: 24467965
[TBL] [Abstract][Full Text] [Related]
33. Galectins as pivotal components in oncogenesis and immune exclusion in human malignancies.
Kapetanakis NI; Busson P
Front Immunol; 2023; 14():1145268. PubMed ID: 36817445
[TBL] [Abstract][Full Text] [Related]
34. 90K (Mac-2 BP) and galectins in tumor progression and metastasis.
Grassadonia A; Tinari N; Iurisci I; Piccolo E; Cumashi A; Innominato P; D'Egidio M; Natoli C; Piantelli M; Iacobelli S
Glycoconj J; 2002; 19(7-9):551-6. PubMed ID: 14758079
[TBL] [Abstract][Full Text] [Related]
35. [Galectins in hematological malignancies--role, functions and potential therapeutic targets].
Wdowiak K; Spychałowicz W; Fajkis M; Wojnar J
Postepy Hig Med Dosw (Online); 2016 Feb; 70():95-103. PubMed ID: 26943306
[TBL] [Abstract][Full Text] [Related]
36. Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasis.
Rodrigues JG; Balmaña M; Macedo JA; Poças J; Fernandes Â; de-Freitas-Junior JCM; Pinho SS; Gomes J; Magalhães A; Gomes C; Mereiter S; Reis CA
Cell Immunol; 2018 Nov; 333():46-57. PubMed ID: 29576316
[TBL] [Abstract][Full Text] [Related]
37. The role of cellular quiescence in cancer - beyond a quiet passenger.
Tomasin R; Bruni-Cardoso A
J Cell Sci; 2022 Aug; 135(15):. PubMed ID: 35929545
[TBL] [Abstract][Full Text] [Related]
38. Tumor-stroma crosstalk: targeting stroma in breast cancer.
Criscitiello C; Esposito A; Curigliano G
Curr Opin Oncol; 2014 Nov; 26(6):551-5. PubMed ID: 25279962
[TBL] [Abstract][Full Text] [Related]
39. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk.
Orozco CA; Martinez-Bosch N; Guerrero PE; Vinaixa J; Dalotto-Moreno T; Iglesias M; Moreno M; Djurec M; Poirier F; Gabius HJ; Fernandez-Zapico ME; Hwang RF; Guerra C; Rabinovich GA; Navarro P
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):E3769-E3778. PubMed ID: 29615514
[TBL] [Abstract][Full Text] [Related]
40. Coupling pathogen recognition to innate immunity through glycan-dependent mechanisms.
Davicino RC; Eliçabe RJ; Di Genaro MS; Rabinovich GA
Int Immunopharmacol; 2011 Oct; 11(10):1457-63. PubMed ID: 21600310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
